Evidence map›Paper›PMID 34194746›Full record

ArticleMolecular and clinical oncology2021

Plasma levels of YKL-40 as a prognostic factor in childhood acute lymphoblastic leukemia.

Alinne Ayulieth Rivas-Alarcón, Yazmin Gómez-Gómez, Jorge Organista-Nava, Marco Antonio Jiménez-López, Ana Berta Rivera-Ramírez, Eloisa Ibarra-Sierra, Mónica Virginia Saavedra-Herrera, Berenice Illades-Aguiar, Marco Antonio Leyva-Vázquez

Open access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Alinne Ayulieth Rivas-AlarcónLaboratorio de Biomedicina Molecular, Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero 39070, México.
Yazmin Gómez-GómezLaboratorio de Biomedicina Molecular, Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero 39070, México.
Jorge Organista-NavaLaboratorio de Biomedicina Molecular, Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero 39070, México.
Marco Antonio Jiménez-LópezDepartamento de Investigación, Instituto Estatal de Cancerología 'Arturo Beltrán Ortega', Acapulco, Guerrero 39570, México.
Ana Berta Rivera-RamírezDepartamento de Investigación, Instituto Estatal de Cancerología 'Arturo Beltrán Ortega', Acapulco, Guerrero 39570, México.
Eloisa Ibarra-SierraDepartamento de Investigación, Instituto Estatal de Cancerología 'Arturo Beltrán Ortega', Acapulco, Guerrero 39570, México.
Mónica Virginia Saavedra-HerreraDepartamento de Investigación, Instituto Estatal de Cancerología 'Arturo Beltrán Ortega', Acapulco, Guerrero 39570, México.
Berenice Illades-AguiarLaboratorio de Biomedicina Molecular, Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero 39070, México.
Marco Antonio Leyva-VázquezLaboratorio de Biomedicina Molecular, Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero 39070, México.
Universidad Autónoma de Guerrero · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

YKL-40, also known as chitinase-3-like protein 1 (CHI3L1), is an inflammatory glycoprotein secreted by different types of cells, such as inflammatory cells. The levels of this protein are elevated in the serum or plasma of patients with different types of cancer, and high concentrations are associated with poor prognosis and short survival in patients with liver, breast, lung, bladder and endometrial cancers. In Mexico, acute lymphoblastic leukemia (ALL) is the most common type of cancer affecting the pediatric population. The prognosis of patients with ALL is difficult to establish. Hence, the objective of the present study was to analyze the plasma levels of YKL-40 in Mexican children with ALL and investigate its role as a prognostic factor. A case-control study was performed in a population of 90 children aged 1-18 years, among whom 45 had ALL and 45 were hematologically healthy. The levels of YKL-40 in plasma samples were measured using ELISA and were found to be significantly higher in children with ALL compared with those in controls (P<0.0001). Children with ALL who had high plasma levels of YKL-40 (≥36.34 ng/ml) had shorter survival compared with those with low levels (<36.34 ng/ml; P<0.05). The findings of the present study revealed that the YKL-40 plasma level, age/initial leukocyte count and central nervous system invasion were associated with the prognosis of children with ALL [odds ratio (OR)=6.06, 95% confidence interval (CI): 1.1-31.6, P=0.03; OR=8.53, 95% CI: 1.2-58.2, P=0.03; and OR=6.45, 95% CI: 1.01-41.2, P=0.04, respectively]. Therefore, YKL-40 plasma levels may serve as a prognostic biomarker in pediatric patients with ALL.

Indexed as

acute lymphoblastic leukemiachildhoodprognosissurvivalYKL-40

Identifiers

PMID34194746
PMCPMC8237154
OpenAlexW3173957281

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.